Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Robert John MootsCinzia CurialeDanielle PeterselCatherine RollandHeather JonesEduardo MyslerPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2018)
Observed differences in treatment response rates between pivotal originator trials and trials of originator biologics and their respective biosimilars may be attributable to fundamental differences in study design and/or baseline patient characteristics, which require further analysis.